156 related articles for article (PubMed ID: 24954008)
1. Folate pathway disruption leads to critical disruption of methionine derivatives in Mycobacterium tuberculosis.
Nixon MR; Saionz KW; Koo MS; Szymonifka MJ; Jung H; Roberts JP; Nandakumar M; Kumar A; Liao R; Rustad T; Sacchettini JC; Rhee KY; Freundlich JS; Sherman DR
Chem Biol; 2014 Jul; 21(7):819-30. PubMed ID: 24954008
[TBL] [Abstract][Full Text] [Related]
2. Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.
Hajian B; Scocchera E; Shoen C; Krucinska J; Viswanathan K; G-Dayanandan N; Erlandsen H; Estrada A; Mikušová K; Korduláková J; Cynamon M; Wright D
Cell Chem Biol; 2019 Jun; 26(6):781-791.e6. PubMed ID: 30930162
[TBL] [Abstract][Full Text] [Related]
3. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Gerum AB; Ulmer JE; Jacobus DP; Jensen NP; Sherman DR; Sibley CH
Antimicrob Agents Chemother; 2002 Nov; 46(11):3362-9. PubMed ID: 12384337
[TBL] [Abstract][Full Text] [Related]
4. Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents.
Tawari NR; Bag S; Raju A; Lele AC; Bairwa R; Ray MK; Rajan MG; Nawale LU; Sarkar D; Degani MS
Future Med Chem; 2015; 7(8):979-88. PubMed ID: 26062396
[TBL] [Abstract][Full Text] [Related]
5. Tea polyphenol epigallocatechin-3-gallate inhibits ergosterol synthesis by disturbing folic acid metabolism in Candida albicans.
Navarro-Martínez MD; García-Cánovas F; Rodríguez-López JN
J Antimicrob Chemother; 2006 Jun; 57(6):1083-92. PubMed ID: 16585130
[TBL] [Abstract][Full Text] [Related]
6. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis.
Chakraborty S; Gruber T; Barry CE; Boshoff HI; Rhee KY
Science; 2013 Jan; 339(6115):88-91. PubMed ID: 23118010
[TBL] [Abstract][Full Text] [Related]
7. Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of antifolates.
Thiede JM; Kordus SL; Turman BJ; Buonomo JA; Aldrich CC; Minato Y; Baughn AD
Sci Rep; 2016 Dec; 6():38083. PubMed ID: 27905500
[TBL] [Abstract][Full Text] [Related]
8. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
da Cunha EF; de Castro Ramalho T; Bicca de Alencastro R; Maia ER
J Biomol Struct Dyn; 2004 Oct; 22(2):119-30. PubMed ID: 15317473
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
[TBL] [Abstract][Full Text] [Related]
10. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
[TBL] [Abstract][Full Text] [Related]
11. Potency boost of a
Aragaw WW; Lee BM; Yang X; Zimmerman MD; Gengenbacher M; Dartois V; Chui WK; Jackson CJ; Dick T
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34161270
[TBL] [Abstract][Full Text] [Related]
12. Transfection studies to explore essential folate metabolism and antifolate drug synergy in the human malaria parasite Plasmodium falciparum.
Wang P; Wang Q; Aspinall TV; Sims PF; Hyde JE
Mol Microbiol; 2004 Mar; 51(5):1425-38. PubMed ID: 14982635
[TBL] [Abstract][Full Text] [Related]
13. Methionine Antagonizes
Howe MD; Kordus SL; Cole MS; Bauman AA; Aldrich CC; Baughn AD; Minato Y
Front Cell Infect Microbiol; 2018; 8():399. PubMed ID: 30483484
[No Abstract] [Full Text] [Related]
14. One of these is not like the others.
Pavelka MS
Trends Microbiol; 2015 Nov; 23(11):668-670. PubMed ID: 26439291
[TBL] [Abstract][Full Text] [Related]
15. Folate metabolism in malaria.
Ferone R
Bull World Health Organ; 1977; 55(2-3):291-8. PubMed ID: 338184
[TBL] [Abstract][Full Text] [Related]
16. Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints.
Kumar A; Siddiqi MI
J Mol Graph Model; 2008 Nov; 27(4):476-88. PubMed ID: 18829358
[TBL] [Abstract][Full Text] [Related]
17. Folic acid metabolism and its disruption by pharmacologic agents.
Huennekens FM; Duffy TH; Vitols KS
NCI Monogr; 1987; (5):1-8. PubMed ID: 3124003
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel DHFR inhibitors for treatment of tuberculosis by combining virtual screening with in vitro activity assay.
Wang N; Ren JX; Xie Y
J Biomol Struct Dyn; 2019 Mar; 37(4):1054-1061. PubMed ID: 29504455
[No Abstract] [Full Text] [Related]
19. Folate Pathway Inhibitors, An Underestimated and Underexplored Molecular Target for New Anti-tuberculosis Agents.
Vassiliades SV; Borges LG; Giarolla J; Parise-Filho R
Mini Rev Med Chem; 2023; 23(17):1711-1732. PubMed ID: 36744693
[TBL] [Abstract][Full Text] [Related]
20. New Mycobacterium avium antifolate shows synergistic effect when used in combination with dihydropteroate synthase inhibitors.
Suling WJ; Seitz LE; Reynolds RC; Barrow WW
Antimicrob Agents Chemother; 2005 Nov; 49(11):4801-3. PubMed ID: 16251337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
